Quantitative Pharmacology Methods for Bispecific T Cell Engagers.

Area of Science:

• Immunology
• Pharmacology
• Computational Biology

Background:

• T Cell Engagers (TCEs) are a novel immuno-oncology therapy bypassing antigen presentation.
• TCE efficacy relies on simultaneous binding to both immune and cancer cells within the tumor microenvironment (TME).
• Maximizing the formation of the drug-target trimer is crucial for enhancing TCE therapeutic effects.

Purpose of the Study:

• To quantitatively investigate how TCE design and target properties influence ternary complex concentration and biodistribution.
• To explore the impact of binding kinetics on TCE efficacy.
• To assess the utility of pre-clinical data for estimating TCE binding affinities.

Main Methods:

• Development of a simplified mathematical model for drug-target interactions, inspired by the "three-body" problem.
• Application of parameter identifiability analysis to steady-state data.
• Analysis of kinetic features of existing clinical and developmental TCE antibodies.
• Evaluation of a quantitative pharmacology model incorporating peripheral drug disposition.

Main Results:

• Steady-state data is sufficient for estimating TCE binding affinity to both targets.
• The study identified common kinetic features among various TCE antibodies.
• The model provides insights into optimizing TCE design for improved efficacy.

Conclusions:

• Mathematical modeling is a valuable tool for understanding and optimizing T Cell Engager therapies.
• Binding kinetics and target properties significantly impact TCE performance in the TME.
• This research supports the development of more effective immuno-oncology treatments.